8 July 2020
Latham & Watkins Advises Ascendis Pharma A/S in Public Offering of ADSs
Advising firms
Deal team
16 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Mark Roeder Lead | Latham & Watkins LLP | Partner | corporate | Silicon Valley |
| John Williams | Latham & Watkins LLP | Associate | corporate | Not stated |
| Traci Biedermann | Latham & Watkins LLP | Associate | corporate | Not stated |
| Tess Bloom | Latham & Watkins LLP | Associate | corporate | Not stated |
| Christopher Lim | Latham & Watkins LLP | Associate | corporate | Not stated |
| Sam Weiner | Latham & Watkins LLP | Partner | compensation and benefits | Los Angeles |
| Janet Hsu | Latham & Watkins LLP | Associate | compensation and benefits | Not stated |
| Jay Metz | Latham & Watkins LLP | Partner | tax | Silicon Valley |
| Lilly Fang | Latham & Watkins LLP | Associate | tax | Not stated |
| Judith Hasko | Latham & Watkins LLP | Partner | intellectual property | Silicon Valley |
| Gavin Liu | Latham & Watkins LLP | Associate | intellectual property | Not stated |
| Ben Haas | Latham & Watkins LLP | Partner | FDA regulatory | Washington DC |
| Héctor Armengod | Latham & Watkins LLP | Partner | FDA regulatory | Brussels |
| Betty Pang | Latham & Watkins LLP | Counsel | FDA regulatory | San Francisco |
| Chad Jennings | Latham & Watkins LLP | Associate | FDA regulatory | Not stated |
| Lacey Henry | Latham & Watkins LLP | Associate | FDA regulatory | Not stated |
13 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 600m ($600M)
- What the figure measures
- Issue size
- Client
- Ascendis Pharma A/SIssuer
- Counterparties
- Not stated